Dr. Coral Olazagasti reviews evolving treatment sequencing for EGFR-mutant NSCLC, focusing on how to approach therapy after progression on first-line osimertinib-based regimens. She highlights datopotamab deruxtecan as an important post-osimertinib and chemotherapy option, especially as clinicians weigh the challenges of TKI-to-TKI sequencing and rechallenge strategies with amivantamab-based regimens. The discussion also distinguishes typical EGFR mutations from atypical EGFR mutations, where treatment decisions may require a more aggressive and individualized approach. Overall, Dr. Olazagasti emphasizes that EGFR-mutant lung cancer care is increasingly personalized, with decisions shaped by mutation type, disease burden, CNS involvement, comorbidities, and patient goals.
Contributors:
Dr. Coral Olazagasti is medical oncologist and an assistant professor at the Sylvester Cancer Center, University of Miami at Miami, Florida.